Leerink Partnrs Upgrades Elanco Animal Health (NYSE:ELAN) to "Strong-Buy"

Leerink Partnrs upgraded shares of Elanco Animal Health (NYSE:ELAN - Free Report) from a hold rating to a strong-buy rating in a report published on Thursday,Zacks.com reports. Leerink Partnrs also issued estimates for Elanco Animal Health's Q4 2025 earnings at $0.15 EPS, FY2025 earnings at $0.85 EPS and FY2026 earnings at $0.95 EPS.

A number of other brokerages have also recently commented on ELAN. William Blair raised Elanco Animal Health from a "market perform" rating to an "outperform" rating in a report on Thursday, June 26th. Wall Street Zen raised Elanco Animal Health from a "hold" rating to a "buy" rating in a report on Saturday, July 5th. Leerink Partners raised Elanco Animal Health from a "market perform" rating to an "outperform" rating and set a $18.00 target price for the company in a report on Thursday. Finally, Stifel Nicolaus increased their target price on Elanco Animal Health from $16.00 to $17.00 and gave the company a "buy" rating in a report on Wednesday, July 2nd. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Elanco Animal Health presently has a consensus rating of "Moderate Buy" and a consensus price target of $16.00.

Elanco Animal Health Price Performance

NYSE ELAN traded down $0.04 during trading hours on Thursday, reaching $14.75. The company's stock had a trading volume of 1,273,325 shares, compared to its average volume of 5,302,881. The firm has a market capitalization of $7.32 billion, a price-to-earnings ratio of 19.93, a P/E/G ratio of 2.88 and a beta of 1.67. Elanco Animal Health has a 1-year low of $8.02 and a 1-year high of $15.78. The company has a debt-to-equity ratio of 0.68, a current ratio of 2.71 and a quick ratio of 1.46. The company's 50-day moving average is $13.82 and its two-hundred day moving average is $11.79.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported $0.37 earnings per share for the quarter, topping analysts' consensus estimates of $0.31 by $0.06. The company had revenue of $1.19 billion during the quarter, compared to analysts' expectations of $1.17 billion. Elanco Animal Health had a return on equity of 7.54% and a net margin of 8.43%. Elanco Animal Health's quarterly revenue was down 1.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.34 EPS. On average, equities analysts predict that Elanco Animal Health will post 0.91 EPS for the current year.

Institutional Investors Weigh In On Elanco Animal Health

A number of large investors have recently made changes to their positions in the stock. Bfsg LLC increased its stake in Elanco Animal Health by 5.1% during the second quarter. Bfsg LLC now owns 26,973 shares of the company's stock worth $385,000 after acquiring an additional 1,321 shares during the last quarter. GAMMA Investing LLC increased its stake in Elanco Animal Health by 540.4% during the second quarter. GAMMA Investing LLC now owns 7,557 shares of the company's stock worth $108,000 after acquiring an additional 6,377 shares during the last quarter. Mitchell & Pahl Private Wealth LLC increased its stake in Elanco Animal Health by 16.9% during the second quarter. Mitchell & Pahl Private Wealth LLC now owns 53,180 shares of the company's stock worth $759,000 after acquiring an additional 7,691 shares during the last quarter. Wealth Enhancement Advisory Services LLC boosted its position in shares of Elanco Animal Health by 8.9% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 11,516 shares of the company's stock worth $169,000 after buying an additional 944 shares during the period. Finally, Westbourne Investments Inc. purchased a new position in shares of Elanco Animal Health during the second quarter worth $170,000. 97.48% of the stock is currently owned by hedge funds and other institutional investors.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.